Illumina's Clinical Sequencing Revenue Seen as Durable Mid-Teens Grower, RBC Capital Markets Says

MT newswire2026/10/05 15:00

11:00 AM EDT, 10/05/2026 (MT Newswires) -- Illumina (ILMN) is positioned for durable mid-teens growth in clinical sequencing revenue, driven by oncology volume growth and easing pricing headwinds, RBC Capital Markets said in a note Sunday. The brokerage said growing adoption of minimal residual disease testing, broad-based tumor profiling approvals, NGS-based colorectal cancer test coverage, and progress in multi-cancer detection should benefit Illumina's instrument and consumables business. RBC also highlighted Illumina's BioInsight business and Billion Cell Atlas, which could provide biological training data for pharma AI models, and expects BioInsight to contribute to an additional 1 to 2 percentage points of growth in fiscal 2027. The brokerage expects academic research demand to bottom in fiscal 2027, while improving reimbursement, low market penetration and oncology growth should support Illumina's clinical business. RBC Capital Markets maintained its outperform rating on the stock and raised its price target to $310 from $230. Illumina shares were up 1.4% in Monday trading. Price: 276.85, Change: +3.81, Percent Change: +1.40

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage

Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.

智通财经•2026/11/09 11:28

Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned

According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.

智通财经•2026/11/09 11:09

Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October

FXStreet•2026/11/09 10:57

The UK Financial Conduct Authority allows banks to submit applications for crypto-related businesses.

AiCoin•2026/11/09 10:45